Retina & Vitreous
Page Content
Brolucizumab 6 mg Drug Product Intended for Commercialization
- A 24-Week, Double-Masked, Multicenter, Two-Arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients with Neovascular Age-Related Macular Degeneration who have Completed the Crth258a2301 Study
- PI: William R. Freeman, MD
Efficacy of Zimura™ in Subjects with Geographic Atrophy (GA)
- A Phase 2B Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Zimura™ (Anti-Complement Factor 5 Aptamer) in Subjects with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration
- PI: William R. Freeman, MD
Intravitreal Opt-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone
- A Dose-Ranging Study of Intravitreal Opt-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-Related Macular Degeneration (Wet AMD)
- PI: Daniel L. Chao, MD, PhD
KESTREL
- A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)
- Nudleman Eric, M.D., Ph.D.
Lampalizumab Administered Intravitreally
- A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
- PI: Henry Ferreyra MD
Lampalizumab in Patients with Geographic Atrophy Secondary
- A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration who have Completed a Roche-Sponsored Study
- PI: Henry Ferreyra, MD
OAKS
- A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy 2nd to Age-Related Macular Degeneration (OAKS)
- Chao Daniel L., M.D., Ph.D.
PANDA
- A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration (PANDA)
- Chao Daniel L., M.D., Ph.D.
PORTAL
- A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-related Macular Degeneration (PORTAL)
- Freeman William R., M.D.
RHINE
- A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema (RHINE)
- Chao Daniel L., M.D., Ph.D.
Rth258 Versus Aflibercept
- A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of Rth258 Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration
- PI: William R. Freeman, Md
- Sub-I: Eric Nudleman, MD, PhD, Daniel L. Chao, MD, PhD
SAPPHIRE
- Suprachoroidal Injection of Triamcinolone Acetonide with IVT Aflibercept in Subjects with Macular Edema Following Rvo (SAPPHIRE)
- Chao Daniel L., M.D., Ph.D.
Suprachoroidal Cls-Ta
- A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal Cls-Ta in Conjunction with Intravitreal Aflibercept in Subjects with Central Retinal Vein Occlusion
- PI: Daniel L. Chao, MD, PhD
- Sub-I: Eric Nudleman, MD, PhD, William R. Freeman, MD
TENAYA
- A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of FARICIMAB in Patients with Age-Related Macular Degeneration (TENAYA)
- Chao Daniel L., M.D., Ph.D.
Show additional content areas below
ContentA1